Recent clinical trials have demonstrated the efficacy Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in slowing the progression of cardiomyopathy regardless of EF in hATTR, which has traditionally been excluded from SGLT2i clinical trials [76]. This evidence concerns the gene SLC5A2 and cardiomyopathy.